Remicade's generic name is infliximab [1].
What is infliximab used for?
Infliximab is a tumor necrosis factor (TNF) inhibitor used to treat various autoimmune conditions [2]. These include rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis [2]. It works by blocking TNF, a protein that can cause inflammation in the body [3].
When does the patent for Remicade (infliximab) expire?
The original patents for Remicade have expired in major markets, allowing for the development and approval of biosimilar versions [4]. For instance, biosimilars began entering the U.S. market in 2016 [5]. DrugPatentWatch.com tracks patent expirations and exclusivity periods for drugs like infliximab [6].
What are the biosimilar alternatives to Remicade?
Several biosimilar versions of infliximab are available. In the United States, these include infliximab-dyyb (Inflectra, Renflexis), infliximab-abda (Renflexis), and infliximab-axx (Avsola) [5][7]. These biosimilars are designed to be highly similar to the reference product, Remicade, in terms of safety, efficacy, and quality [5].
How do infliximab biosimilars compare to Remicade?
Biosimilars are not considered exact copies but are highly similar to the reference biologic product [5]. They undergo rigorous testing to demonstrate no clinically meaningful differences in safety, purity, and potency compared to the reference product [5]. The FDA has approved infliximab biosimilars based on scientific evidence showing they are interchangeable with Remicade, meaning they can be substituted for the reference product [5][8].
What are the potential risks and side effects of infliximab?
Like other TNF inhibitors, infliximab carries risks, including serious infections due to its immunosuppressive effects [3]. Patients may experience infusion reactions, which can include fever, chills, rash, or difficulty breathing [3]. Other potential side effects include headache, nausea, abdominal pain, and an increased risk of certain cancers [3]. It is important for patients to discuss these risks with their healthcare provider [3].
Where can I find more information on infliximab drug patents?
Detailed information regarding patent expiries, exclusivity periods, and patent challenges for infliximab and other drugs can be found on DrugPatentWatch.com [6].
Sources:
[1] https://www.drugpatentwatch.com/drug/remicade
[2] https://www.drugpatentwatch.com/drug/infliximab
[3] https://www.medicalnewstoday.com/articles/infliximab
[4] https://www.ashp.org/drug-synthesis/drug-development/biosimilars/biosimilar-drug-exclusivity-and-patent-information
[5] https://www.fda.gov/drugs/biosimilars/information-about-biosimilar-and-interchangeable-biologics
[6] https://www.drugpatentwatch.com/
[7] https://www.bmj.com/content/370/bmj.m3403
[8] https://www.about.com/medications/infliximab/